SignaBlok to Highlight SCHOOL Therapeutic Peptides at the 2015 Essential Protein Engineering Summit

    SHREWSBURY, MA, April 15, 2015 /24-7PressRelease/ -- SignaBlok, Inc. today announced that it will present preclinical data showcasing company's peptide therapeutic programs in oncology, sepsis and rheumatoid arthritis (RA) at the Therapeutics Stream at the 2015 Essential Protein Engineering Summit (PEGS) Annual Meeting being held May 4-8, 2015 at the Seaport World Trade Center in Boston.

By 2018, the global Peptide Therapeutics market is expected to reach over $25 billion. SignaBlok's presentation highlights a novel model of cell signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and related inhibitory peptides (SCHOOL peptides) that employ new, ligand-independent mechanisms of action. Nanotechnology-enabled targeted delivery of these peptides will be demonstrated. As an exemplary use case, preclinical studies of the TREM-1-specific SCHOOL peptide inhibitor in free and macrophage-specific nanoparticle-bound forms, most carried out in cells and animal models of cancer and sepsis, will be presented. TREM-1 is a specific cell receptor expressed on macrophages that serves as an inflammation amplifier and is critically involved in cancer, sepsis, RA, atherosclerosis, and other inflammation-associated conditions. In summary, future perspectives for SCHOOL peptides will be highlighted.

Oral Presentation:

Wednesday, May 6, 2015

2nd Annual Peptide Therapeutics - Conquering Disease / Therapeutics Stream
Session Title: Peptide Advances
Ligand-Independent Inhibitory Peptides (SCHOOL Peptides) in Medicine: Recent Advances and Future Perspectives
11:55 AM ET
Seaport World Trade Center, 200 Seaport Blvd, Boston

SignaBlok is developing a new class of therapies - SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy. Additional information about SignaBlok is available at http://www.signablok.com.

# # #